This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

The gastrointestinal tract and GLP-1 RA treatment

The gastrointestinal (GI) tract is central when it comes to glucagon-like peptide-1 (GLP-1): physiologically, the peptide is secreted from the L-cells in the small intestine upon nutrient intake; moreover, when given orally in a tablet, the GLP-1 receptor agonist (RA) semaglutide is absorbed in the stomach, and the most common side effects of treatment with GLP-1 RAs are GI disturbances.

In this collection, we introduce articles describing accumulated clinical evidence of the intertwined relationships between the GI tract and the functions and effects of GLP-1 RAs. 

Free access to a collection of digital features from congresses


Throughout the year, Novo Nordisk research is presented at several major congresses. We welcome you to explore the Novo Nordisk sponsored science that we is presented using ScienceHub, which gives you free access to a comprehensive collection of digital features extending the official congress materials. The materials include audio poster tours, infographics, podcasts, videos featuring our presenters and supplementary slide decks.

Most recent articles and congress materials

Upcoming congresses

Latest congresses